Prevalencija post-COVID sindroma: sistematski pregled i meta-analiza.
BMC public health
Sažetak istraživanja
Pozadina Od početka pandemije korona virusa 2019. (COVID-19), broj osoba koje se oporavljaju od infekcije COVID-19 se povećao. Post-COVID sindrom ili PCS, koji se definiše kao znakovi i simptomi koji se razvijaju tokom ili nakon infekcije u skladu s COVID-19, nastavljaju se nakon 12 sedmica i ne objašnjavaju se alternativnom dijagnozom, također je privukao pažnju. Sistematski smo pregledali i odredili objedinjenu procjenu prevalencije PCS-a širom svijeta na osnovu objavljene literature.
Metode Relevantni članci iz baza podataka Web of Science, Scopus, PubMed, Cochrane Library i Ovid MEDLINE pregledani su korišćenjem Preferred Reporting Items za sistematske preglede i meta-analize vođene sistematskim procesom pretraživanja. Uključene studije su bile na engleskom jeziku, objavljene od januara 2020. do aprila 2024., imale su ukupnu prevalenciju PCS-a kao jedan od proučavanih ishoda, uključivale su ljudsku populaciju s potvrđenom dijagnozom COVID-19 i provjerene 12 sedmica nakon infekcije COVID-19 ili kasnije. Kao primarni mjeren ishod, objedinjena prevalencija PCS-a procijenjena je iz meta-analize podataka o prevalenci PCS-a izvađenih iz pojedinačnih studija, koja je sprovedena putem modela slučajnih efekata. Ova studija je registrovana na PROSPERO (CRD42023435280).
Rezultati Četrdeset osam studija je ispunilo kriterijume podobnosti i uključeno je u ovaj pregled. 16 je prihvaćeno za meta-analizu kako bi se procijenila objedinjena prevalencija PCS-a širom svijeta, koja je iznosila 41,79% (95% interval pouzdanosti [CI] 39,70-43,88%, I 2 = 51%, p = 0,03). Na osnovu različitih procena ili vremenskih tačaka praćenja nakon akutne infekcije COVID-19, prevalencija PCS procenjena na vremenske tačke ≥ 3., ≥ 6. i ≥ 12. meseci iznosila je svaki od 45,06% (95% CI: 41,25-48,87%), 41,30%CI: 41,30%CI:-93,30% CI:-93,30% i 41,32% (95% CI: 39,27-43,37%), respektivno. Prevalencija PCS stratificiranog po spolu procijenjena je na 47,23% (95% CI: 44,03-50,42%) kod muškaraca i 52,77% (95% CI: 49,58-55,97%) kod žena. Na osnovu kontinentalnih regiona, objedinjena prevalencija PCS procijenjena je na 46,28% (95% CI: 39,53%-53,03%) u Evropi, 46,29% (95% CI: 35,82%-56,77%) u Americi, 49,79% (95% CI: 05% CI: 05%-9,5% u Aziji). 42,41% (95% CI: 0,00%-90,06%) u Australiji.
Zaključak Procjene prevalencije u ovoj meta-analizi mogle bi se koristiti u daljim sveobuhvatnim studijama o PCS, koje bi mogle omogućiti razvoj boljih planova upravljanja PCS kako bi se smanjio efekat PCS na zdravlje stanovništva i povezano ekonomsko opterećenje.
Prikaži originalni naslov i sažetak na engleskom
Post-COVID syndrome prevalence: a systematic review and meta-analysis.
Background Since the Coronavirus disease 2019 (COVID-19) pandemic began, the number of individuals recovering from COVID-19 infection have increased. Post-COVID Syndrome, or PCS, which is defined as signs and symptoms that develop during or after infection in line with COVID-19, continue beyond 12 weeks, and are not explained by an alternative diagnosis, has also gained attention. We systematically reviewed and determined the pooled prevalence estimate of PCS worldwide based on published literature.
Methods Relevant articles from the Web of Science, Scopus, PubMed, Cochrane Library, and Ovid MEDLINE databases were screened using a Preferred Reporting Items for Systematic Reviews and Meta-Analyses-guided systematic search process. The included studies were in English, published from January 2020 to April 2024, had overall PCS prevalence as one of the outcomes studied, involved a human population with confirmed COVID-19 diagnosis and undergone assessment at 12 weeks post-COVID infection or beyond. As the primary outcome measured, the pooled prevalence of PCS was estimated from a meta-analysis of the PCS prevalence data extracted from individual studies, which was conducted via the random-effects model. This study has been registered on PROSPERO (CRD42023435280).
Results Forty eight studies met the eligibility criteria and were included in this review. 16 were accepted for meta-analysis to estimate the pooled prevalence for PCS worldwide, which was 41.79% (95% confidence interval [CI] 39.70-43.88%, I 2 = 51%, p = 0.03). Based on different assessment or follow-up timepoints after acute COVID-19 infection, PCS prevalence estimated at ≥ 3rd, ≥ 6th, and ≥ 12th months timepoints were each 45.06% (95% CI: 41.25-48.87%), 41.30% (95% CI: 34.37-48.24%), and 41.32% (95% CI: 39.27-43.37%), respectively. Sex-stratified PCS prevalence was estimated at 47.23% (95% CI: 44.03-50.42%) in male and 52.77% (95% CI: 49.58-55.97%) in female. Based on continental regions, pooled PCS prevalence was estimated at 46.28% (95% CI: 39.53%-53.03%) in Europe, 46.29% (95% CI: 35.82%-56.77%) in America, 49.79% (95% CI: 30.05%-69.54%) in Asia, and 42.41% (95% CI: 0.00%-90.06%) in Australia.
Conclusion The prevalence estimates in this meta-analysis could be used in further comprehensive studies on PCS, which might enable the development of better PCS management plans to reduce the effect of PCS on population health and the related economic burden.
Izvorni podaci
- DOI
- 10.1186/s12889-024-19264-5
- PMID
- 38965510
- PMCID
- PMC11223303
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom